“…Currently, there are no commercial drugs containing this unit, but many studies have demonstrated the potential applicability of imidazo[1,5- a ]pyridines in pharmacology. In Figure 3 , diverse biologically active derivatives of imidazo[1,5- a ]pyridine are depicted, including agonists of cannabinoid receptor type 2 (CB2R) (compound 1 ), serotonin 5-hydroxytryptamine (5-HT4) antagonists (compound 2 ), inhibitors of hypoxia-inducible factor 1α (HIF-1α) (compound 3 ), inhibitors of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) (compound 4 ), cribrostatin-6 (compound 5 ), phosphodiesterase 10A inhibitors (compound 6 ), tubulin polymerization inhibitors (compound 7 ), neurokinin antagonists, kinase inhibitors, and various chemotherapeutic agents that have been evaluated [ 65 , 75 , 76 , 87 , 92 , 101 , 102 , 103 , 104 , 105 , 106 , 107 ]. In addition, in the past, this nucleus has been investigated as a selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease [ 108 ].…”